Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
- 18 October 2002
- journal article
- Published by Springer Nature in Oncogene
- Vol. 21 (49) , 7593-7597
- https://doi.org/10.1038/sj.onc.1205932
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 33 references indexed in Scilit:
- Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assaysBritish Journal of Cancer, 2002
- Genomic analysis of metastasis reveals an essential role for RhoCNature, 2000
- Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerThe Lancet, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- p53 Mutation as a Genetic Trait of Typical Medullary Breast CarcinomaJNCI Journal of the National Cancer Institute, 1999
- Perceptions of Herceptin®: A Monoclonal Antibody for the Treatment of Breast CancerCancer Biotherapy & Radiopharmaceuticals, 1999
- Inflammatory breast carcinoma incidence and survivalCancer, 1998
- Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?Breast Cancer Research and Treatment, 1998
- A simple p53 functional assay for screening cell lines, blood, and tumors.Proceedings of the National Academy of Sciences, 1995